Quantcast

Latest cyclophosphamide Stories

2008-10-27 09:00:41

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive and Medical Officer, will present at the Oppenheimer & Co. 19th Annual Healthcare Conference on Monday, November 3, 2008 at 3:20 pm ET at the Waldorf-Astoria Hotel in New York City. Dr. Lewis will provide an overview of the Company and its clinical development programs. The presentation will be webcast live and can be accessed by visiting the Investor Relations section at...

2008-10-07 03:00:08

Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) today announced that a global Phase III study of Rituxan(R) (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia (CLL) compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study. An independent...

2008-09-30 09:01:00

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Maxim Group Growth Investor Conference on Tuesday, October 7, 2008 at 3:30 pm ET in the Morosco room at the Grand Hyatt Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its clinical development programs. The presentation will be webcast live and can be accessed by visiting the Investor Relations section at www.ziopharm.com. The webcast...

2008-09-29 09:00:58

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Third Annual JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 3:30 at Le Meridien Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its clinical development programs. The presentation will be webcast live and can be accessed by visiting the Investor Relations section at www.ziopharm.com. The webcast will be...

2008-06-17 15:00:00

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that researchers from Johns Hopkins University have published encouraging results from a two-year study evaluating the treatment of aggressive relapsing-remitting multiple sclerosis with Revimmune(TM), Accentia's patent-pending, novel usage of an approved chemotherapeutic drug (cyclophosphamide) in an ultra-high dose, pulsed intravenous administration for four hours daily over four days. Administered in this fashion,...

2008-06-16 15:00:49

U.S. scientists say they've found a short-term, high dose of the immune-suppressing drug cyclophosphamide can slow the progression of multiple sclerosis. Johns Hopkins researchers said their study involving nine people, most of whom had failed all other treatments, suggests new ways to treat the disease that tends to progress relentlessly. We didn't expect such a dramatic return of function, said Dr. Douglas Kerr, an associate professor of neurology at the Johns Hopkins University School...

2008-06-14 03:00:00

By Hicks, David G Kulkarni, Swati * Context.-Overexpression of human epidermal growth factor receptor 2 (HER2) is an adverse prognostic parameter for patients with breast cancer. Patients with HER2- positive tumors are, however, likely to gain significant benefit from targeted therapy with trastuzumab. Four largescale trials have assessed the efficacy and safety of adjuvant trastuzumab. In all 4 trials, disease-free survival and overall survival were significantly improved with adjuvant...

4ac1f8b199937adee7b608bdc5223c621
2005-07-13 12:29:12

NEW YORK -- Women with early breast cancer who receive higher-than-standard doses of two chemotherapy drugs (epirubicin and cyclophosphamide) as "add-on" therapy are at increased risk of subsequently developing cancer of the blood, researchers have found. Although add-on therapy with these drugs for early breast cancer has increased the number of long-term survivors, a small risk of secondary acute myeloid leukemia (AML), with or without a pre-leukemia known as myelodysplastic syndrome (MDS),...

2005-06-10 06:37:53

Immune-targeted rituximab shows good results in two trials HealthDay News -- The cancer drug rituximab may benefit lupus patients with central nervous system (CNS) complications, according to a new U.S. study. "Rituximab appears to be quite effective. It is a kinder, gentler form of treatment lasting up to six months with a low risk of side effects, compared to previous treatments of high-dose steroids and chemotherapy," researcher Michael Neuwelt of the University of California, San...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related